卡培他滨联合顺铂与卡培他滨联合多西他赛治疗三阴性复发转移性乳腺癌的临床研究  

Comparison of Capecitabine plus Cisplatin with Capecitabine plus Docetaxel for treatment of recurrent metastatic triple negative breast cancer

作　　者：张彦武[1] 吕以东[1] 牛耀东[1] 严文君[1] 冯爱强[1] 

机构地区：[1]郑州大学第三附属医院乳腺科,河南郑州450052

出　　处：《中国现代医学杂志》2017年第10期66-70,共5页China Journal of Modern Medicine

基　　金：河南省高等学校重点科研项目(No:16A320064)

摘　　要：目的比较卡培他滨联合顺铂与卡培他滨联合多西他赛治疗三阴性复发转移性乳腺癌的临床疗效及其安全性。方法将58例三阴性复发转移性乳腺癌病例随机分为A组和B组,A组进行卡培他滨联合顺铂方案化疗,B组进行卡培他滨联合多西他赛方案化疗,21 d为1个周期,至少应用2个周期。结果 A组26例,B组32例,可评价疗效A组22例,B组30例,两组患者基线情况无统计学差异。A、B两组的完全缓解率(9.1%vs 3.3%,P=0.781)差异无统计学意义,A组的疾病控制率(86.4%vs 53.3%,P=0.012)和客观缓解率(50.0%vs23.3%,P=0.046)均较B组高,差异具有统计学意义。A、B两组的中位无进展生存期(PFS)分别为7.5和5.5个月,差异具有统计学意义(P=0.015);中位总生存期(OS)两组分别为19.7个月和13.3个月,差异具有统计学意义(P=0.037)。A、B两组常见的Ⅲ~Ⅳ度不良反应为白细胞减少和粒细胞减少。其他常见的不良反应多为Ⅰ~Ⅱ度,其中脱发发生率A组<B组(15.4%vs 56.3%,P=0.001),差异具有统计学意义。其余不良反应在两组间均无统计学意义(P>0.05)。结论卡培他滨联合顺铂方案的疗效较卡培他滨联合多西他赛方案有优势,其不良反应可耐受,在临床实践中可作为复发转移性三阴性乳腺癌解救治疗的有效选择之一。Objective To compare the efficacy and safety of Capecitabine plus Cisplatin （XP） and Capecitabine plus Docetaxel （TX） in treatment of recurrent metastatic triple negative breast cancer （TNBC）. Methods In this study 58 patients with recurrent metastatic TNBC were randomly distributed to group A （26 cases） and group B （32 cases）. The patients in the group A were treated with XP regimen and those in the group B were treated with TX regimen for 21 days as a cycle, at least two cycles were applied. Results The group A and the group B had consistent baseline. There were 22 cases in the group A and 30 cases in the group B evaluable for their clinical responses. No significant difference was found in the complete remission rate between the two groups （9.1% vs 3.3% ,P = 0.781）. The disease control rate （86.4% vs 53.3%,P = 0.012） and the objective remission rate （50.0% vs 23.3%,P = 0.046） of the group A were significantly higher than those of the group B. There were significant differences in the median PFS （7.5 months vs 5.5 months, P = 0.015） and the median OS （19.7 months vs 13.3 months, P = 0.037） between the groups A and B. The common degree m and IV adverse reactions in the two groups were leucopenia and granulopenia. Other common adverse reactions in the two groups were of degree I and 11. The two reroups showed no significant differences in the incidences of adverse reactions except for alopecia （15.4% vs 56.3%, P = 0.001）. Conclusions The clinical effieacy of XP regimen is significantly superior to that of TX regimen. Its adverse reactions are tolerable. The XP regimen can be one of the effective options for the treatment of recurrent metastasis TNBC in clinical practice.

关 键 词：乳腺肿瘤 卡培他滨 顺铂 多西他赛 

分 类 号：R737.9[医药卫生—肿瘤]